First-line XELOX plus bevacizumab followed by XELOX plus bevacizumab or single-agent bevacizumab as maintenance therapy in patients with metastatic colorectal cancer: The phase III MACRO TTD study

  1. Díaz-Rubio, E.
  2. Gómez-España, A.
  3. Massutí, B.
  4. Sastre, J.
  5. Abad, A.
  6. Valladares, M.
  7. Rivera, F.
  8. Safont, M.J.
  9. de Prado, P.M.
  10. Gallén, M.
  11. González, E.
  12. Marcuello, E.
  13. Benavides, M.
  14. Fernández-Martos, C.
  15. Losa, F.
  16. Escudero, P.
  17. Arrivi, A.
  18. Cervantes, A.
  19. Dueñas, R.
  20. López-Ladrón, A.
  21. Lacasta, A.
  22. Llanos, M.
  23. Tabernero, J.M.
  24. Antón, A.
  25. Aranda, E.
Journal:
Oncologist

ISSN: 1083-7159,  1549-490X

Year of publication: 2012

Volume: 17

Issue: 1

Pages: 15-25

Type: Article

DOI: 10.1634/THEONCOLOGIST.2011-0249 GOOGLE SCHOLAR lock_openOpen access editor
Data source: Scopus